About OnCusp
OnCusp is a company based in New York (United States) founded in 2021. OnCusp has raised $100 million across 1 funding round from investors including Marshall Wace, Orbimed and Novo Holdings. OnCusp offers products and services including CUSP06 and Pipeline Development. OnCusp operates in a competitive market with competitors including Helsinn, Aster Insights, Abogen Biosciences, CancerVax and Linical, among others.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$100 M (USD)
in 1 rounds
-
Latest Funding Round
$100 M (USD), Series A
Jan 04, 2024
-
Investors
Marshall Wace
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OnCusp
OnCusp offers a comprehensive portfolio of products and services, including CUSP06 and Pipeline Development.
Drug targeting Platinum-Resistant Ovarian Cancer in clinical trials
Transforms molecules into innovative cancer therapeutics globally
Funding Insights of OnCusp
OnCusp has successfully raised a total of $100M through 1 strategic funding round. The most recent funding activity was a Series A round of $100 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OnCusp
OnCusp has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Marshall Wace, Orbimed and Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked |
Investor details for OnCusp
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OnCusp
Investment portfolio details for OnCusp
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OnCusp
Detailed financials for OnCusp
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oncusp Comparisons
Peer comparison for OnCusp
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OnCusp
OnCusp operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Helsinn, Aster Insights, Abogen Biosciences, CancerVax and Linical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Oncology therapeutics are developed, manufactured, and commercialized by Helsinn.
|
|
| Locked | Locked | Locked |
Contract-based oncology clinical trial services are provided by Aster Insights.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics are developed for cancer and infectious diseases.
|
|
| Locked | Locked | Locked |
Cancer vaccine research and development is conducted by CancerVax.
|
|
| Locked | Locked | Locked |
Full-service CRO operations are conducted across more than 20 countries.
|
Detailed competitors of OnCusp
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oncusp
Complete news archive for OnCusp
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OnCusp
OnCusp was founded in 2021 and raised its 1st funding round 3 years after it was founded.
OnCusp is headquartered in New York, United States. It is registered at New York, New York, United States.
OnCusp is a funded company, having raised a total of $100M across 1 funding round to date.
OnCusp cro offering clinical development services for oncology drugs through providing healthcare solutions, biopharma outsourcing, cro, clinical development, full service, and oncology. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
OnCusp offers CUSP06 and Pipeline Development.
OnCusp has 10 investors. Key investors include Marshall Wace, Orbimed, Novo Holdings, F-Prime Capital, and Sofinnova.